• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience.与来那度胺单药治疗相比，在来那度胺基础上加用CD20单克隆抗体可提高复发/难治性慢性淋巴细胞白血病患者的缓解率并延长生存期——MD安德森癌症中心的经验。
Br J Haematol. 2015 Oct;171(2):281-284. doi: 10.1111/bjh.13377. Epub 2015 Mar 30.
2
Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis.来那度胺治疗复发/难治性慢性淋巴细胞白血病患者的疗效：一项系统评价和荟萃分析。
Ann Hematol. 2016 Sep;95(9):1473-82. doi: 10.1007/s00277-016-2719-6. Epub 2016 Jun 21.
3
Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.来那度胺维持治疗既往接受过治疗的慢性淋巴细胞白血病（CONTINUUM）：一项随机、双盲、安慰剂对照的3期试验。
Lancet Haematol. 2017 Nov;4(11):e534-e543. doi: 10.1016/S2352-3026(17)30168-0. Epub 2017 Sep 25.
4
Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.序贯使用奥法妥木单抗和来那度胺治疗复发难治性慢性淋巴细胞白血病和小淋巴细胞淋巴瘤。
Leuk Lymphoma. 2015 Mar;56(3):645-9. doi: 10.3109/10428194.2014.935369.
5
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.苯达莫司汀+利妥昔单抗化学免疫疗法及来那度胺维持治疗复发难治性慢性淋巴细胞白血病和小淋巴细胞淋巴瘤：威斯康星肿瘤学网络研究
Br J Haematol. 2016 Apr;173(2):283-91. doi: 10.1111/bjh.13957. Epub 2016 Feb 23.
6
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Venetoclax 治疗伴有 17p 缺失的复发或难治性慢性淋巴细胞白血病：一项多中心、开放标签、2 期研究。
Lancet Oncol. 2016 Jun;17(6):768-778. doi: 10.1016/S1470-2045(16)30019-5. Epub 2016 May 10.
7
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.高危骨髓增生异常综合征和急性髓系白血病患者序贯使用阿扎胞苷和来那度胺：一项单臂1/2期研究。
Lancet Haematol. 2015 Jan;2(1):e12-20. doi: 10.1016/S2352-3026(14)00026-X. Epub 2014 Dec 22.
8
Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.奥法妥珠单抗维持治疗与观察在复发性慢性淋巴细胞白血病中的疗效比较（PROLONG）：一项开放标签、多中心、随机、3 期研究。
Lancet Oncol. 2015 Oct;16(13):1370-9. doi: 10.1016/S1470-2045(15)00143-6. Epub 2015 Sep 13.
9
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.来那度胺用于高危慢性淋巴细胞白血病一线治疗后的维持治疗（CLLM1）：一项随机、双盲、3期研究的最终结果
Lancet Haematol. 2017 Oct;4(10):e475-e486. doi: 10.1016/S2352-3026(17)30171-0. Epub 2017 Sep 12.
10
Monoclonal antibody therapy of chronic lymphocytic leukaemia.单克隆抗体治疗慢性淋巴细胞白血病。
Best Pract Res Clin Haematol. 2010 Mar;23(1):133-43. doi: 10.1016/j.beha.2010.01.006.

引用本文的文献

1
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.来那度胺和利妥昔单抗治疗初治和复发 CLL 患者的疗效和反应预测因素。
Blood Adv. 2019 May 14;3(9):1533-1539. doi: 10.1182/bloodadvances.2019031336.
2
Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.在不适合接受氟达拉滨、环磷酰胺和利妥昔单抗（FCR）方案的老年晚期慢性淋巴细胞白血病患者中，作为一线治疗方案，加用个体化剂量来那度胺联合苯丁酸氮芥和利妥昔单抗的可行性和疗效。
Haematologica. 2019 Jan;104(1):147-154. doi: 10.3324/haematol.2018.193854. Epub 2018 Aug 16.

本文引用的文献

1
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.奥滨尤妥珠单抗联合苯丁酸氮芥治疗伴有合并症的 CLL 患者。
N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8.
2
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia.来那度胺可诱导老年慢性淋巴细胞白血病患者产生持久缓解。
Blood. 2013 Aug 1;122(5):734-7. doi: 10.1182/blood-2013-04-495341. Epub 2013 Jun 25.
3
Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.来那度胺和利妥昔单抗作为挽救疗法治疗复发或难治性慢性淋巴细胞白血病患者的 II 期研究。
J Clin Oncol. 2013 Feb 10;31(5):584-91. doi: 10.1200/JCO.2012.42.8623. Epub 2012 Dec 26.
4
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.利用合成致死性治疗 ABC 弥漫性大 B 细胞淋巴瘤。
Cancer Cell. 2012 Jun 12;21(6):723-37. doi: 10.1016/j.ccr.2012.05.024.
5
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.来那度胺作为老年慢性淋巴细胞白血病患者的初始治疗。
Blood. 2011 Sep 29;118(13):3489-98. doi: 10.1182/blood-2011-03-339077. Epub 2011 Jul 1.
6
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.来那度胺单药治疗未经治疗的慢性淋巴细胞白血病。
J Clin Oncol. 2011 Mar 20;29(9):1175-81. doi: 10.1200/JCO.2010.29.8133. Epub 2010 Dec 28.
7
lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.来那度胺增强利妥昔单抗治疗的CD20+肿瘤细胞的自然杀伤细胞和单核细胞介导的抗体依赖性细胞毒性。
Clin Cancer Res. 2008 Jul 15;14(14):4650-7. doi: 10.1158/1078-0432.CCR-07-4405.
8
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.来那度胺可使复发难治性慢性淋巴细胞白血病患者获得完全缓解和部分缓解。
Blood. 2008 Jun 1;111(11):5291-7. doi: 10.1182/blood-2007-12-130120. Epub 2008 Mar 11.
9
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.来那度胺治疗复发或难治性慢性淋巴细胞白血病患者的临床疗效：一项II期研究结果
J Clin Oncol. 2006 Dec 1;24(34):5343-9. doi: 10.1200/JCO.2005.05.0401. Epub 2006 Nov 6.

The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience.

作者信息

Thompson Philip A, Rozovski Uri, Keating Michael J, Stingo Francesco, Smith Susan C, Wierda William G, Falchi Lorenzo, O'Brien Susan M, Estrov Zeev, Burger Jan A, Ferrajoli Alessandra

机构信息

Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.

Department of Biostatistics, MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Br J Haematol. 2015 Oct;171(2):281-284. doi: 10.1111/bjh.13377. Epub 2015 Mar 30.

DOI:10.1111/bjh.13377
PMID:25824652
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4589497/
Abstract
摘要